William Blair Issues Pessimistic Outlook for SLP Earnings

Simulations Plus, Inc. (NASDAQ:SLP - Free Report) - Stock analysts at William Blair reduced their Q3 2026 EPS estimates for Simulations Plus in a research note issued to investors on Monday, January 27th. William Blair analyst M. Smock now anticipates that the technology company will post earnings of $0.43 per share for the quarter, down from their prior estimate of $0.44. William Blair has a "Outperform" rating on the stock. The consensus estimate for Simulations Plus' current full-year earnings is $1.09 per share.

A number of other analysts have also recently weighed in on SLP. Stephens started coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an "overweight" rating and a $39.00 target price on the stock. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a research report on Thursday, October 24th. StockNews.com lowered Simulations Plus from a "hold" rating to a "sell" rating in a research note on Monday, November 4th. Finally, KeyCorp boosted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Simulations Plus Stock Down 0.7 %

Simulations Plus stock traded down $0.24 on Thursday, hitting $34.09. The company's stock had a trading volume of 99,934 shares, compared to its average volume of 307,617. The company has a fifty day moving average price of $30.46 and a 200-day moving average price of $32.50. The firm has a market cap of $684.77 million, a P/E ratio of 85.23 and a beta of 0.82. Simulations Plus has a one year low of $24.00 and a one year high of $51.22.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently modified their holdings of SLP. First Horizon Advisors Inc. boosted its stake in Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company's stock valued at $26,000 after acquiring an additional 370 shares during the last quarter. nVerses Capital LLC raised its holdings in Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company's stock worth $38,000 after buying an additional 1,100 shares during the period. Quantbot Technologies LP bought a new position in Simulations Plus in the third quarter valued at approximately $59,000. US Bancorp DE boosted its holdings in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock valued at $159,000 after buying an additional 1,343 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company's stock worth $311,000 after acquiring an additional 456 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company's stock.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares of the company's stock, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 19.40% of the company's stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.